Oxford, UK, November 07, 2022 (B3C newswire) -- OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran®, its ultrasound-based drug delivery platform, announces that it has appointed Jérôme Marzinski as its Chief Executive Officer with immediate effect.
Read full article here.
Durham, NC and Seattle, WA, January 12, 2025 (Business Wire) -- Tune Therapeutics has raised $175 million in Series B funding to...
Ribometrix Names William S. Marshall, Ph.D., as CEO to Drive Breakthrough RNA-Targeting Therapeutics
Durham, NC, January 09, 2025 (Globe newswire) -- Ribometrix has appointed Dr. William S. Marshall as CEO and Dr. Katie Warner as CSO,...
San Francisco & Princeton, NJ, January 10, 2025 (Business Wire) -- Kardigan launches with $300 million in funding and a mission to cure...
Comentários